HAMBURG, Germany and OXFORD, England, September 20 /PRNewswire-FirstCall/ -- Evotec today announced that Joern Aldag, President & CEO of Evotec, will present at the UBS Global Life Sciences Conference at 11.00 a.m. US Eastern Time on Wednesday, 28 September 2005, at the Grand Hyatt in New York.
The audio portion of the presentation will be a webcast via the UBS website at www.ibb.ubs.com. The accompanying slides are available on request. Please e-mail to: investor.relations@evotec.com.
About Evotec AG
Evotec is a leader in the discovery and development of the next generation of novel small molecule drugs both through its own discovery programmes and through contract research partnerships. In its own discovery programmes, the Company specialises in finding new treatments for diseases of the central nervous system (CNS), which were expanded in March 2005 through the acquisition of ENS Holdings, Inc. The Company now has a number of products in late stage pre-clinical development, the most advanced of which, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease, is expected to enter clinical trials later this year.
In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative solutions from drug target to clinic through an unmatched range of inteÃ?Âgrated capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
With over 600 people located in Hamburg, Germany and near Oxford, UK, Evotec is committed to generating value for its partners, shareholders and employees through a sustainable strategy that balances short and long-term business opporÃ?Âtunities.
www.evotec.com Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone: +49-(0)40-560-81-286 anne.hennecke@evotec.com
Evotec AGCONTACT: Contact: Evotec AG: Anne Hennecke, Director, Investor Relations &Corporate Communications, Phone: +49-(0)40-560-81-286,anne.hennecke@evotec.com
